Nail changes induced by chemotherapeutic agents

Chemotherapy-induced nail changes: an unsightly nuisance.

P.S. is a 53-year-old female patient with stage IIB breast cancer. In November 2000, she received Adriamycin (Pfizer Inc., New York, NY) and Cytoxan (Bristol-Myers Squibb, New York, NY), along with Herceptin (Genentech, Inc., South San Francisco, CA), as part of a clinical trial. In July 2002, the patient was found to have a left supraclavicular axillary recurrence. Because of this recurrence, ...

Bone Marrow Osteoblast Damage by Chemotherapeutic Agents

Hematopoietic reconstitution, following bone marrow or stem cell transplantation, requires a microenvironment niche capable of supporting both immature progenitors and stem cells with the capacity to differentiate and expand. Osteoblasts comprise one important component of this niche. We determined that treatment of human primary osteoblasts (HOB) with melphalan or VP-16 resulted in increased p...

Evaluation of Chemotherapeutic Agents

This fourth, thoroughly revised, edition of Calmette's well-known manual aims to bring together the maximum of information which will be of value to the bacteriologist in his daily work. It is based largely on the techniques utilized at the Pasteur Institute in Paris. The topics included differ from those found in similar manuals in this country which are usually texts of laboratory diagnosis a...

Enzymes as Chemotherapeutic Agents

Medication Errors in Administration of Chemotherapeutic Agents: an Observational Study

Chemotherapy medication errors may lead to potentially harmful consequences while most of them could be preventable. This study aims to determine the incidence and type of drug handling and administration errors among the nurses and to identify possible contributing factors. Setting of the study was a teaching hospital affiliated to Shahid Beheshti University of Medic...